Journal article · 2022 · Open access
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine, 387(3), 205–216 · Published 4 June 2022 · DOI 10.1056/nejmoa2206038
In brief
“Tirzepatide Once Weekly for the Treatment of Obesity” is a 2022 journal article by Ania M. Jastreboff and 10 co-authors, published in New England Journal of Medicine. OpenAlex counts 4,787 citations as of 22 November 2026. It is open access: the full text is free to read at New England Journal of Medicine.
- Citations
- 4,787
- Most cited in
- 2026 (1,927)
- Field-weighted impact
- 312.97
- References
- 28
- Authors
- 11
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L. E., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C. M., & Stefański, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
MLA 9
Jastreboff, Ania M., et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, vol. 387, no. 3, 2022, pp. 205–216. https://doi.org/10.1056/nejmoa2206038.
Chicago
Jastreboff, Ania M., Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Lisa E. Connery, Breno Alves, Arihiro Kiyosue, et al. 2022. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine 387 (3): 205–216. https://doi.org/10.1056/nejmoa2206038.
Harvard
Jastreboff, A. M. et al. (2022) ‘Tirzepatide Once Weekly for the Treatment of Obesity’, New England Journal of Medicine, 387(3), pp. 205–216. doi:10.1056/nejmoa2206038.
IEEE
A. M. Jastreboff et al., “Tirzepatide Once Weekly for the Treatment of Obesity,” New England Journal of Medicine, vol. 387, no. 3, pp. 205–216, 2022, doi: 10.1056/nejmoa2206038.
BibTeX
@article{jastreboff2022tirzepatide,
title = {{Tirzepatide Once Weekly for the Treatment of Obesity}},
author = {Jastreboff, Ania M. and Aronne, Louis J. and Ahmad, Nadia N. and Wharton, Sean and Connery, Lisa E. and Alves, Breno and Kiyosue, Arihiro and Zhang, Shuyu and Liu, Bing and Bunck, Mathijs C. M. and Stefański, Adam},
journal = {New England Journal of Medicine},
year = {2022},
volume = {387},
number = {3},
pages = {205--216},
doi = {10.1056/nejmoa2206038},
url = {https://doi.org/10.1056/nejmoa2206038}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2012 | 1 | |
| 2014 | 1 | |
| 2017 | 1 | |
| 2020 | 1 | |
| 2022 | 154 | |
| 2023 | 610 | |
| 2024 | 839 | |
| 2025 | 1,250 | |
| 2026 | 1,927 |
Its field-weighted citation impact is 312.97: it has been cited 312.97 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- tirzepatide
- obesity
- weight loss
- GLP-1 receptor agonists
- GIP receptor agonist
- glucose-dependent insulinotropic polypeptide
- glucagon-like peptide-1
- dose escalation
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L. E., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C. M., & Stefański, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/nejmoa2206038
How many times has this paper been cited?
4,787 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at New England Journal of Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, Sean Wharton, Lisa E. Connery, Breno Alves, Arihiro Kiyosue, Shuyu Zhang, Bing Liu, Mathijs C. M. Bunck, Adam Stefański.
What is the DOI of this paper?
10.1056/nejmoa2206038, permanently at https://doi.org/10.1056/nejmoa2206038. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.